CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
May 5th 2025
The strongest connections I’ve made are with others who have also been through their own cancer journeys.
FDA Grants Full Approval for Keytruda Combination in Lung Cancer
August 20th 2018The Food and Drug Administration (FDA) has granted a full approval to frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), based on findings from the phase 3 KEYNOTE-189 trial.
PARP Inhibitors May Bring New Hope to Patients With Small Cell Lung Cancer
July 17th 2018Investigators at The University of Texas MD Anderson Cancer Center in Houston discovered that adding the PARP inhibitor veliparib to a standard chemotherapy regimen improved overall responses rates (ORR) in patients with relapsed small cell lung cancer (SCLC).
A Closer Look at Long-Term Outcomes in Young Cancer Survivors
July 10th 2018The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.
FDA Grants Priority Review to Frontline Keytruda Combination in Metastatic NSCLC
July 2nd 2018The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.
Insurance Disparities Among Medicaid Patients with NSCLC Leads to Worse Survival
June 21st 2018According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.